Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.

• ClinicalTrials.gov Identifier: NCT02863822
• Recruitment Status: Withdrawn
• First Posted: August 11, 2016
• Last Update Posted: April 17, 2018
• Sponsor: Advocate Health Care
• Information provided by (Responsible Party): Hina Omar,MD, Advocate Health Care

Study Description

Brief Summary:

The purpose of this study is to evaluate the effectiveness of the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet in functional dyspepsia (FD). The investigators will compare education in the low FODMAP diet to a standard healthy diet for improving symptoms in FD.

Condition or disease	Intervention/treatment	Phase
Dyspepsia; Dietary Modification	Behavioral: Low FODMAP Diet; Behavioral: Choose My Plate Diet	Not Applicable

Detailed Description:

Functional Dyspepsia (FD) is defined by the Rome III criteria as bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning in the absence of structural or systemic disease that can explain the symptoms. These symptoms have been present for at least 3 months with symptom onset 6 months prior to the diagnosis.

The low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet has been studied in irritable bowel syndrome (IBS) patients and has been shown to have modest benefit in a limited number of small studies. The diet is generally started by complete elimination of fructose, lactose, fructans, galactans, and polyols. Following symptom improvement, these groups are reintroduced one at a time while the patient monitors for symptoms.

Although the low FODMAP diet has never been formally studied in patients with functional dyspepsia, we have noted the FD patients report improvement in their symptoms on the diet. This improvement could be explained by reduction in duodenal and gastric distention with the low FODMAP diet or a change in the duodenal flora.

To date, there have been no randomized trials evaluating dietary modification in FD. The purpose of this study is to evaluate the efficacy of the low FODMAP diet in functional dyspepsia. The investigator's hypothesis is that the addition of the FODMAP diet to standard medical treatment will result in improved symptom control in patients with functional dyspepsia.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Investigator)
• Primary Purpose: Treatment
• Official Title: A Prospective, Randomized, Investigator Blinded, Controlled Trial to Evaluate the Effectiveness of Dietary Modification in Patients With Functional Dyspepsia
• Study Start Date: September 2016
• Estimated Primary Completion Date: June 2018
• Estimated Study Completion Date: June 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: Low FODMAP; Subjects will be given dietary education in the low FODMAP diet, which they will continue for 4 weeks. Subjects will then followup with the dietician and subjects with a symptomatic response will be given instructions for reintroduction.	Behavioral: Low FODMAP Diet; Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
Active Comparator: Choose My Plate; Subjects will receive dietary counseling in the choose my plate diet as defined by choosemyplate.gov. Subjects will also receive 2 dietician visits, 4 weeks apart.	Behavioral: Choose My Plate Diet; Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.

Outcome Measures

Primary Outcome Measures :

1. Self report of adequate relief [ Time Frame: Week 7 (after 4 weeks of diet modification) ]
   Self report of adequate relief of dyspepsia symptoms for the previous 7 days. This information will be collected at week 7. This measure is considered clinically relevant and has been tested for responsiveness in FD

Secondary Outcome Measures :

1. Improvement in the NDI short form [ Time Frame: Week 7 (after 4 weeks of diet modification) ]
   The NDI short form is a validated questionnaire used to determine the severity of symptoms related to dyspepsia. It can be used to evaluate change over time.
2. Improvement in the Global Overall Symptom Scale [ Time Frame: Week 7 (after 4 weeks of diet modification) ]
3. Continued Improvement in the Global Overall Symptom Scale [ Time Frame: Week 10 (after low FODMAP reintroduction) ]
4. Continued Improvement in the NDI short form [ Time Frame: Week 10 (after low FODMAP reintroduction) ]
   The NDI short form is a validated questionnaire used to determine the severity of symptoms related to dyspepsia. It can be used to evaluate change over time.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Men and women 18 years and older
• Diagnosis of FD with either PDS or EPS as measured by Rome III Criteria
• Patients describing inadequate relief of dyspepsia symptoms
• Endoscopy performed in the last 3 years and negative for an organic cause for dyspeptic symptoms
• H pylori negative by non-invasive testing or biopsy. Patients with a history of successfully eradicated H pylori will be included if follow-up testing by stool antigen, urea breath testing, or biopsy is negative
• Celiac disease excluded by serologies or biopsy

Exclusion Criteria:

• Patients with IBS predominant symptoms that are not well controlled
• Patients with a diagnosis of GERD who have uncontrolled heartburn
• History of esophagitis, ulcer disease, or other organic upper GI disease, including a diagnosis of celiac disease, gastroparesis, or vascular disorders of the upper GI tract
• History of surgery involving the esophagus, stomach, or duodenum
• Known lactose intolerance, unless symptoms persist on a lactose free diet
• Known fructose intolerance unless symptoms persist on a fructose free diet
• Patients undergoing active titration of any medications
• Pregnant or breastfeeding women
• Prisoners

Contacts and Locations

Locations

United States, Illinois

Advocate Lutheran General Hospital

Park Ridge, Illinois, United States, 60068

Sponsors and Collaborators

Advocate Health Care

Investigators

• Principal Investigator: Hina Omar, MD; Advocate Lutheran General Hospital
• Principal Investigator: Marc Fine, MD; Advocate Lutheran General Hospital

More Information

Publications:

Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012 Aug;142(8):1510-8. doi: 10.3945/jn.112.159285. Epub 2012 Jun 27.

Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, Smith S, Gibson PR, Muir JG. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010 Aug;25(8):1366-73. doi: 10.1111/j.1440-1746.2010.06370.x.

Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K, Akkermans LM. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009 Jun 21;15(23):2887-92.

Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol. 2003 Nov;98(11):2454-9.

Talley NJ, Van Zanten SV, Saez LR, Dukes G, Perschy T, Heath M, Kleoudis C, Mangel AW. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther. 2001 Apr;15(4):525-37.

Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, Lacy BE, DiBaise JK, Prather CM, Abraham BP, El-Serag HB, Moayyedi P, Herrick LM, Szarka LA, Camilleri M, Hamilton FA, Schleck CD, Tilkes KE, Zinsmeister AR. Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. Gastroenterology. 2015 Aug;149(2):340-9.e2. doi: 10.1053/j.gastro.2015.04.020. Epub 2015 Apr 25.

Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. Aliment Pharmacol Ther. 2001 Feb;15(2):207-16.

• Responsible Party: Hina Omar,MD, Hina Omar, MD Chief Resident, Advocate Health Care
• ClinicalTrials.gov Identifier: NCT02863822
• Other Study ID Numbers: 2015-203
• First Posted: August 11, 2016
• Last Update Posted: April 17, 2018
• Last Verified: April 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: No plan to make individual participant data available. Poster presentation, Manuscript publication, oral presentations are planned.

Keywords provided by Hina Omar,MD, Advocate Health Care:

Functional Dyspepsia; Low FODMAP; Dietary Modification

Additional relevant MeSH terms:

Dyspepsia; Signs and Symptoms, Digestive